Related references
Note: Only part of the references are listed.SEOM clinical guidelines for the management of adult soft tissue sarcomas
Xavier Garcia del Muro Solans et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Axel Le Cesne et al.
EUROPEAN JOURNAL OF CANCER (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function
Beatriz Pardo et al.
MEDICAL ONCOLOGY (2012)
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular abberations
Jaap Verweij et al.
EUROPEAN JOURNAL OF CANCER (2010)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations
S. P. Myrand et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis (R)) in cancer patients
Juan Jose Perez-Ruixo et al.
CLINICAL PHARMACOKINETICS (2007)
New emerging drugs in soft tissue sarcoma
Amalia Milano et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors
SJ Xia et al.
EUROPEAN JOURNAL OF CANCER (2005)
Medical progress: Soft-tissue sarcomas in adults
MA Clark et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
M Van Glabbeke et al.
EUROPEAN JOURNAL OF CANCER (2002)
Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
A Taamma et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Contribution of molecular genetic data to the classification of sarcomas
M Ladanyi et al.
HUMAN PATHOLOGY (2000)